title: Safety and efficacy of a turkey herpesvirus vector laryngotracheitis vaccine for chickens.
abstract: Turkey herpesvirus vector laryngotracheitis vaccine (HVT/LT) expressing the glycoprotein B gene of laryngotracheitis virus (LTV) has been developed. In vitro growth kinetics of HVT/LT were similar to those of parental turkey herpesvirus (HVT), FC-126 strain. Genetic and phenotypic stabilities of HVT/LT after in vitro (in cell culture) or in vivo (in chickens) passage were confirmed by various assays, including Southern blot analysis, western blot analysis, and an indirect immunofluorescence assay. Safety of HVT/LT was assessed by an overdose study as well as by a backpassage study in specific-pathogen-free (SPF) chickens. The overdose study indicated that HVT/LT did not cause any adverse effects in chickens. The backpassage study confirmed that HVT/LT does not revert to virulence after five passages in chickens. The vaccine did not transmit laterally from vaccinated chickens to commingled nonvaccinated chickens. Efficacy of HVT/LT was evaluated in SPF layer chickens after vaccination by the subcutaneous route at 1 day of age. The majority of the vaccinated chickens (92%-100%) were protected against challenge with virulent LTV at 7 wk of age. Efficacy of HVT/LT was further evaluated in broiler chickens from a commercial source after in ovo vaccination to embryos at 18 days of incubation. After challenge with virulent LTV at 21 and 35 days of age, 67% and 87% of HVT/LT-vaccinated chickens did not develop LT clinical signs, respectively, while 100% (21 days of age) and 73% (35 days of age) of the challenge control chickens showed clinical signs of LT. These results suggest that HVT/LT is a safe and efficacious vaccine for control of laryngotracheitis (LT).
authors.forename: Motoyuki
authors.initials: M
authors.lastname: Esaki
authors.forename: Lauren
authors.initials: L
authors.lastname: Noland
authors.forename: Tim
authors.initials: T
authors.lastname: Eddins
authors.forename: Alecia
authors.initials: A
authors.lastname: Godoy
authors.forename: Sakiko
authors.initials: S
authors.lastname: Saeki
authors.forename: Shuji
authors.initials: S
authors.lastname: Saitoh
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yasuda
authors.forename: Kristi Moore
authors.initials: KM
authors.lastname: Dorsey
mesh_terms: D000818:Animals; D002645:Chickens; D019084:Fluorescent Antibody Technique, Indirect / Q000662:veterinary; D006566:Herpesviridae Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D001352:Herpesvirus 1, Gallid / Q000276:immunology*; D026002:Herpesvirus 1, Meleagrid / Q000276:immunology; D022283:Herpesvirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects*; D008380:Marek Disease / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D011201:Poultry Diseases / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D013047:Specific Pathogen-Free Organisms; D014611:Vaccination / Q000662:veterinary; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*
chemical_list: D022283:Herpesvirus Vaccines; D014613:Vaccines, Attenuated; D014759:Viral Envelope Proteins; C067381:GB protein, Infectious laryngotracheitis virus